Rosuvastatin attenuates inflammation, apoptosis and fibrosis in a rat model of cyclosporine-induced nephropathy

Am J Nephrol. 2013;37(1):7-15. doi: 10.1159/000345990. Epub 2012 Dec 21.

Abstract

Background/aim: Cyclosporine (CsA)-induced kidney injury is characterized by renal dysfunction with inflammatory cell infiltrations, apoptosis and fibrosis. Pleiotropic effects of statins may exert anti-inflammatory, antiapoptotic and antifibrotic actions beyond lipid control. The aim of this study is to investigate whether rosuvastatin (RUS) has anti-inflammatory, antiapoptotic and antifibrotic effects on chronic CsA-induced nephropathy in a rat model.

Methods: Male Sprague-Dawley rats fed a low-sodium diet were divided into three treatment groups: control (0.9% saline injection), CsA (15 mg/kg/day by subcutaneous injection), CsA + RUS (10 mg/kg/day by gastric gavage). Renal function, CsA level and lipid levels were measured at the end of 4 weeks. The expression of ED-1, transforming growth factor-β(1) (TGF-β(1)) and α-smooth muscle actin (α-SMA) for inflammation and fibrosis were examined by Western blot analysis. The expression levels of apoptosis-associated factors were examined by Western blot analysis. Apoptosis was evaluated using the terminal deoxynucleotidyl transferase-mediated biotin nick end-labeling (TUNEL) method.

Results: Kidney function was decreased in CsA-treated rats compared with controls, which was attenuated by RUS. RUS did not affect the lipid level or the blood CsA level. TUNEL staining showed that RUS inhibited CsA-induced tubular apoptosis. RUS decreased CsA-induced increased expression of Bax/Bcl-2 ratio. The expressions of ED-1, α-SMA, TGF-β(1), Smad2/3, Smad4 and p-JNK were increased in CsA-treated rats, which were attenuated by RUS. Tubular atrophy and interstitial fibrosis in CsA-treated rats were attenuated by RUS supplementation.

Conclusion: RUS supplementation attenuates proinflammatory and apoptosis-related factors and inhibits the fibrotic pathways including the smad-dependent and smad-independent pathways in a rat model of CsA-induced nephropathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / metabolism
  • Animals
  • Apoptosis / drug effects
  • Cadherins / metabolism
  • Cyclosporine / adverse effects*
  • Drug Evaluation, Preclinical
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Fluorobenzenes / pharmacology
  • Fluorobenzenes / therapeutic use*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Immunosuppressive Agents / adverse effects*
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Kidney / metabolism
  • Kidney / pathology
  • Kidney Diseases / chemically induced
  • Kidney Diseases / metabolism
  • Kidney Diseases / pathology
  • Kidney Diseases / prevention & control*
  • MAP Kinase Signaling System / drug effects
  • Male
  • Nitric Oxide Synthase Type II / metabolism
  • Proteins / metabolism
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Rosuvastatin Calcium
  • Smad Proteins / metabolism
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use*
  • Transforming Growth Factor beta1 / metabolism

Substances

  • Actins
  • Cadherins
  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Immunosuppressive Agents
  • Proteins
  • Pyrimidines
  • Smad Proteins
  • Sulfonamides
  • Tgfb1 protein, rat
  • Transforming Growth Factor beta1
  • smooth muscle actin, rat
  • Cyclosporine
  • Rosuvastatin Calcium
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Extracellular Signal-Regulated MAP Kinases
  • JNK Mitogen-Activated Protein Kinases